Allurion Technologies

Expanding Obesity Solutions Will Boost Prospects Amid Launch Uncertainties

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

20 Apr 25

Updated

20 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-83.1%

7D

27.8%

Loading

1Y

-83.1%

7D

27.8%

You can edit this narrative until Nov 21 12:15 AM. Then, changes will post as Updates.

Author's Valuation

US$777.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 20 Nov 25

Fair value Increased 20%

ALUR: Expanded Brazil Hospital Network Will Drive Obesity Therapy Access

Narrative Update on Allurion Technologies: Analyst Price Target Revision Analysts have raised their price target for Allurion Technologies from $5.83 to $7.00. They cite improved revenue growth projections and a slight uplift in expected profit margin as the primary factors behind the upward revision.

Shared on 24 Sep 25

Fair value Decreased 30%

A significant reduction in consensus revenue growth forecasts has driven the analyst price target for Allurion Technologies down from $8.38 to $5.83. What's in the News Allurion Technologies was unable to file its next 10-Q by the required SEC deadline.

Shared on 15 Aug 25

With consensus forecasts for both revenue growth and net profit margin remaining steady, analysts have left their fair value estimate for Allurion Technologies unchanged at $8.38. What's in the News Allurion Technologies announced a strategic Canadian distribution partnership with Minogue Medical Inc., leveraging Minogue's national network of obesity care providers to expand access to Allurion's metabolically healthy weight loss program.

Shared on 01 May 25

Fair value Decreased 21%

Shared on 24 Apr 25

AnalystConsensusTarget Fair Value

US$7

77.0% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

25.83%

Consumer Services revenue growth rate

0.41%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

12.50%

Calculation

US$7.80m

Earnings '28

x

21.80x

PE Ratio '28

=

US$170.08m

Market Cap '28

US$170.08m

Market Cap '28

/

17.06m

No. shares '28

=

US$9.97

Share Price '28

US$9.97 Share Price '28

Discounted to 2025 @ 12.50% p.a.

=

US$7.00

Fair Value '25